 Genetic Therapy
"Genetic Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
| Descriptor ID |
D015316
|
| MeSH Number(s) |
E02.095.301 E05.393.420.301
|
| Concept/Terms |
Genetic Therapy- Genetic Therapy
- Genetic Therapies
- Therapies, Genetic
- Therapy, Genetic
- Therapy, DNA
- DNA Therapy
Genetic Therapy, Somatic- Genetic Therapy, Somatic
- Genetic Therapies, Somatic
- Somatic Genetic Therapies
- Somatic Genetic Therapy
- Therapies, Somatic Genetic
- Therapy, Somatic Genetic
Genetic Therapy, Gametic- Genetic Therapy, Gametic
- Gametic Genetic Therapies
- Gametic Genetic Therapy
- Genetic Therapies, Gametic
- Therapies, Gametic Genetic
- Therapy, Gametic Genetic
|
Below are MeSH descriptors whose meaning is more general than "Genetic Therapy".
Below are MeSH descriptors whose meaning is more specific than "Genetic Therapy".
This graph shows the total number of publications written about "Genetic Therapy" by people in this website by year, and whether "Genetic Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 3 | 4 | | 2003 | 5 | 2 | 7 | | 2004 | 1 | 1 | 2 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 1 | 3 | | 2007 | 5 | 0 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 4 | 1 | 5 | | 2010 | 7 | 1 | 8 | | 2011 | 5 | 2 | 7 | | 2012 | 1 | 3 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 3 | 0 | 3 | | 2015 | 4 | 2 | 6 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Genetic Therapy" by people in Profiles.
-
Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 07 01; 78(7):834-841.
-
Alarcón-Arís D, Pavia-Collado R, Miquel-Rio L, Coppola-Segovia V, Ferrés-Coy A, Ruiz-Bronchal E, Galofré M, Paz V, Campa L, Revilla R, Montefeltro A, Kordower JH, Vila M, Artigas F, Bortolozzi A. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
-
Chu Y, Bartus RT, Manfredsson FP, Olanow CW, Kordower JH. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
-
Barker RA, Björklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
-
Sposito AC, Carmo HR, Barreto J, Sun L, Carvalho LSF, Feinstein SB, Zanotti I, Kontush A, Remaley A. HDL-Targeted Therapies During Myocardial Infarction. Cardiovasc Drugs Ther. 2019 06; 33(3):371-381.
-
Price RJ, Fisher DG, Suk JS, Hanes J, Ko HS, Kordower JH. Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
-
Savolainen M, Emerich D, Kordower JH. Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
-
Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
-
van Karnebeek CD, Bowden K, Berry-Kravis E. Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. Pediatr Neurol. 2016 12; 65:1-13.
-
Kordower JH. AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|